Hospital admissions due to exacerbations: number of participants · patients with chronic obstructive pulmonary disease
Fixed‐dose combination aclidinium/formoterol showed no clear difference in hospital admissions due to exacerbations: number of participants compared with placebo (moderate certainty).
1 finding from 1 review
Improvement in symptoms: number of participants with clinically significant improvement: using TDI focal score (≥ 1 unit) · patients with chronic obstructive pulmonary disease
Fixed‐dose combination aclidinium/formoterol leads to higher improvement in symptoms: number of participants with clinically… compared with placebo (high certainty).
1 finding from 1 review
Lung function · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Adverse events (not including serious adverse events): number of participants · patients with chronic obstructive pulmonary disease
Fixed‐dose combination aclidinium/formoterol showed no clear difference in adverse events (not including serious adverse events): number of… compared with placebo (moderate certainty).
1 finding from 1 review
Exacerbations (number of people experiencing ≥ 1 exacerbations) · adults with bronchiectasis
Macrolides probably leads to lower ≥ 1 exacerbation compared with placebo (moderate certainty).
1 finding from 1 review
Exacerbation frequency · children with bronchiectasis
Macrolides may leads to lower exacerbation frequency compared with placebo (low certainty).
1 finding from 1 review
Hospitalisation (any cause) · children with bronchiectasis
Macrolides showed no clear difference in hospitalisation: all‐cause compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · children with bronchiectasis
Macrolides showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortality · children with bronchiectasis
1 finding from 1 review
Quality of life not reported · children with bronchiectasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hospitalisation (any cause) · adults with bronchiectasis
Macrolides showed no clear difference in hospitalisation: all cause compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · adults with bronchiectasis
Macrolides showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortality · adults with bronchiectasis
1 finding from 1 review
Quality of life: 1a. Average endpoint scores on various scales (MSQoL‐54, high = good) ‐ short term · adults with bronchiectasis
1 finding from 1 review
Quality of life: change · adults with bronchiectasis
1 finding from 1 review
Number of participants who were not cured at · children < 24 months with ongoing symptoms (cough/wheeze) post‐acute bronchiolitis
Antibiotics showed no clear difference in number of participants who were not cured at compared with placebo or no treatment (low certainty).
1 finding from 1 review
Number of participants rehospitalised for a respiratory illness · children < 24 months with ongoing symptoms (cough/wheeze) post‐acute bronchiolitis
Antibiotics showed no clear difference in number of participants rehospitalised for a respiratory illness compared with placebo or no treatment (low certainty).
1 finding from 1 review
Proportion of participants with recurrent wheeze · children < 24 months with ongoing symptoms (cough/wheeze) post‐acute bronchiolitis
Antibiotics showed no clear difference in proportion of participants with recurrent wheeze compared with placebo or no treatment (low certainty).
1 finding from 1 review
Prolonged abstinence at longest · smokers with COPD
Pharmacological treatment leads to higher prolonged abstinence at longest compared with placebo (high certainty).
5 findings from 1 review
RR 2.53 [1.83, 3.5]
4 studies · 1429 participants
High
RR 2.6 [1.29, 5.24]
1 study · 370 participants
High
RR 2.03 [1.26, 3.28]
2 studies · 503 participants
Moderate
Show 2 more findings
Health‐related quality of life · people with asthma
Vilanterol and fluticasone furoate showed no clear difference in health‐related quality of life compared with placebo (moderate certainty).
1 finding from 1 review
MD 0.3
2012 participants
Moderate